Total Payments
$4,066
2024 Payments
$1,771
Companies
28
Transactions
193
Medicare Patients
598
Medicare Billing
$61,041
Payment Breakdown by Category
Food & Beverage$3,904 (96.0%)
Education$161.50 (4.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,904 | 191 | 96.0% |
| Education | $161.50 | 2 | 4.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,061 | 61 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $659.51 | 24 | $0 (2024) |
| Janssen Biotech, Inc. | $355.08 | 12 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $351.67 | 15 | $0 (2024) |
| GENZYME CORPORATION | $228.09 | 12 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $169.86 | 7 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $149.46 | 6 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $135.06 | 8 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $112.18 | 6 | $0 (2024) |
| QOL Medical, LLC | $108.94 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,771 | 89 | ABBVIE INC. ($537.05) |
| 2023 | $1,392 | 72 | AbbVie Inc. ($423.85) |
| 2022 | $498.96 | 25 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($96.96) |
| 2021 | $220.53 | 4 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($194.45) |
| 2020 | $67.00 | 1 | Janssen Biotech, Inc. ($67.00) |
| 2019 | $116.71 | 2 | Janssen Biotech, Inc. ($94.50) |
All Payment Transactions
193 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Gastroenterology | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/13/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $9.39 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $23.77 | General |
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Gastroenterology | ||||||
| 11/12/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $16.85 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/11/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $18.96 | General |
| Category: GI | ||||||
| 11/08/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/24/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $45.76 | General |
| Category: LIVER DISEASE | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Gastroenterology | ||||||
| 10/22/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: IMMUNOLOGY | ||||||
| 10/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Immunology | ||||||
| 10/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: LIVER DISEASE | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Immunology | ||||||
| 09/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Immunology | ||||||
| 09/19/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Gastroenterology | ||||||
| 09/11/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $9.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/06/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $16.55 | General |
| Category: GI | ||||||
| 09/05/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $28.44 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 451 | 527 | $145,320 | $44,108 |
| 2022 | 8 | 147 | 180 | $45,337 | $16,933 |
Total Patients
598
Total Services
707
Medicare Billing
$61,041
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 55 | 58 | $36,482 | $9,838 | 27.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 47 | 50 | $17,350 | $6,163 | 35.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 48 | $8,832 | $4,307 | 48.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 61 | 85 | $6,697 | $4,302 | 64.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 42 | 42 | $5,645 | $3,692 | 65.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 37 | 37 | $19,610 | $2,972 | 15.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 52 | 52 | $18,200 | $2,541 | 14.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 19 | 19 | $8,360 | $2,153 | 25.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 35 | $4,515 | $2,087 | 46.2% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 17 | 22 | $7,832 | $1,985 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 46 | 54 | $3,396 | $1,947 | 57.3% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 11 | 11 | $4,257 | $1,166 | 27.4% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 14 | 14 | $4,144 | $956.26 | 23.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 24 | 28 | $9,716 | $4,157 | 42.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 49 | $9,016 | $3,683 | 40.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 17 | 17 | $10,693 | $3,252 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 30 | $2,314 | $1,814 | 78.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 17 | 17 | $2,270 | $1,595 | 70.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $6,360 | $973.50 | 15.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $4,200 | $896.73 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 15 | $767.10 | $561.26 | 73.2% |
About Charles Closson
Charles Closson is a Internal Medicine healthcare provider based in Danville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/25/2016. The National Provider Identifier (NPI) number assigned to this provider is 1497117717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Charles Closson has received a total of $4,066 in payments from pharmaceutical and medical device companies, with $1,771 received in 2024. These payments were reported across 193 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($3,904).
As a Medicare-enrolled provider, Closson has provided services to 598 Medicare beneficiaries, totaling 707 services with total Medicare billing of $61,041. Data is available for 2 years (2022–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Danville, KY
- Active Since 03/25/2016
- Last Updated 07/18/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1497117717
Products in Payments
- XIFAXAN (Drug) $497.44
- DUPIXENT (Biological) $397.95
- LINZESS (Drug) $395.11
- RINVOQ (Biological) $339.65
- ENTYVIO (Biological) $253.80
- CREON (Drug) $170.88
- TRULANCE (Drug) $162.07
- STELARA (Biological) $152.58
- Linzess (Drug) $135.06
- VOQUEZNA (Drug) $112.18
- SKYRIZI (Biological) $108.64
- TREMFYA (Drug) $108.00
- ZEPOSIA (Drug) $100.72
- REMICADE (Biological) $94.50
- OFEV (Drug) $80.72
- RESMETIROM (Drug) $71.27
- Sucraid (Drug) $60.27
- DIFICID (Drug) $55.60
- ZENPEP (Drug) $51.35
- SUCRAID (Drug) $48.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Danville
Dr. Christopher Still, D.o, D.O
Internal Medicine — Payments: $461,951
Internal Medicine $461,951
Dr. Brendan Carry, M.d, M.D
Internal Medicine — Payments: $209,824
Internal Medicine $209,824
Prince Anand, M.d, M.D
Internal Medicine — Payments: $188,555
Internal Medicine $188,555
Jessica Mckee, D.o, D.O
Internal Medicine — Payments: $57,390
Internal Medicine $57,390
Michael Caplan, Md, MD
Internal Medicine — Payments: $41,374
Internal Medicine $41,374
Dr. Mark Reginato, M.d, M.D
Internal Medicine — Payments: $23,997
Internal Medicine $23,997